8-K: Inhibrx Reports First Quarter 2025 Financial Results, Cites Progress on Clinical Programs

Inhibrx Biosciences announced its Q1 2025 financial results, highlighting progress in its clinical trials and upcoming data readouts.

Summary

• Inhibrx Biosciences reported its financial results for the first quarter of 2025.
• The company has two programs in ongoing clinical trials with data readouts expected within the year.
• As of March 31, 2025, Inhibrx had cash and cash equivalents of $216.5 million, compared to $152.6 million as of December 31, 2024.
• The cash balance increased following the receipt of $100.0 million in gross principal in January 2025 under a loan and security agreement with Oxford Finance LLC.
• Research and development expenses were $36.9 million during the first quarter of 2025, compared to $63.9 million during the first quarter of 2024.
• General and administrative expenses were $6.0 million during the first quarter of 2025, compared to $10.0 million during the first quarter of 2024.
• Net loss was $43.3 million during the first quarter of 2025, or $2.80 per share, compared to a net loss of $78.7 million during the first quarter of 2024, or $5.77 per share.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the increased cash position, decreased expenses, and upcoming data readouts, although the company is still operating at a loss.

Positives

• Cash and cash equivalents increased significantly to $216.5 million.
• Research and development expenses decreased, likely due to the spin-off of the INBRX-101 program.
• General and administrative expenses decreased due to fewer stock options and lower professional service expenses.
• Net loss decreased significantly year-over-year.
• The company has multiple upcoming data readouts for its clinical programs.

Negatives

• The company reported a net loss of $43.3 million for the quarter.
• The company incurred other expenses of $0.4 million during the first quarter of 2025.

Risks

• The company's forward-looking statements are subject to risks and uncertainties, including those related to clinical trial outcomes, regulatory approvals, and the ability to raise capital.
• The company's ability to advance therapeutic candidates into, and successfully complete, clinical trials is uncertain.
• The company's ability to raise funds needed to satisfy its capital requirements depends on financial, economic and market conditions.

Future Outlook

The company anticipates data readouts from its INBRX-109 and INBRX-106 clinical trials throughout 2025.

Industry Context

Inhibrx is operating in the competitive biopharmaceutical industry, focusing on developing novel biologic therapeutic candidates. The company's progress in clinical trials and upcoming data readouts are crucial for its future growth and market positioning.

Comparison to Industry Standards

• It is difficult to compare Inhibrx directly to industry standards without more specific information on the stage and type of their clinical programs.
• However, companies like Regeneron, Amgen, and Genentech are benchmarks for successful biopharmaceutical companies with diverse pipelines.
• The cash position of $216.5 million provides Inhibrx with runway to fund its clinical programs, but the burn rate will need to be monitored against peers.
• The decrease in R&D expenses following the spin-off is a unique situation and may not be directly comparable to other companies' R&D spending.

Stakeholder Impact

• Shareholders may be encouraged by the increased cash position and progress in clinical trials.
• Employees may benefit from the company's continued investment in research and development.
• Patients may benefit from the development of new therapeutic candidates.

Next Steps

• The company expects data from the registration-enabling Phase 2 trial in unresectable or metastatic conventional chondrosarcoma during the third quarter of 2025.
• The company expects initial data on the colorectal cancer expansion cohort in the third quarter of 2025.
• The company expects interim data from the Ewing sarcoma expansion cohort in the second half of 2025.
• The company expects initial Phase 2 data from the randomized Phase 2/3 trial in head and neck squamous cell carcinoma in combination with KEYTRUDA during the fourth quarter of 2025.
• The company expects interim data from the Phase 1/2 checkpoint inhibitor refractory or relapsed non-small cell lung cancer during the fourth quarter of 2025.

Key Dates

Keywords

Inhibrx, Financial Results, Clinical Trials, INBRX-109, INBRX-106, Biopharmaceutical, Data Readouts, Q1 2025